Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.
Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis
Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.
Insight into the Biosimilar Prescribing Habits of Rheumatologists
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis
Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.
Tofacitinib Promising for COVID-19 Pneumonia
(Reuters)—Pfizer Inc. said on June 16 its oral rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published…
Polymyositis-Dermatomyositis Tied to Arrhythmias in Young, Middle-Aged Adults
(Reuters Health)—Young and middle-aged adults with polymyositis-dermatomyositis are more likely to have arrhythmias in general, and supraventricular arrhythmias in particular, than matched controls without these rare rheumatic conditions, a U.S. study suggests.1 Researchers examined retrospective data on adults hospitalized between 2016 and 2018, including 32,085 patients with polymyositis-dermatomyositis and 320,850 age-matched controls. Overall, both women…
Rituximab Seems Safe & Effective for Systemic Sclerosis
NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…
Are Medicare Beneficiaries with Knee OA Receiving Enough Conservative Care?
NEW YORK (Reuters Health)—Non-surgical care for knee osteoarthritis (OA) is uncommon among older adults, especially in regions of the U.S. where total knee arthroplasty rates are high, a large retrospective analysis shows.1 “As rheumatologists, we often think of knee arthroplasty as the last resort, after patients have tried and failed more conservative treatments, such as…
Bipartisan DXA Bill Under Consideration in Congress
The Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act would set a $98 floor for Medicare reimbursement for the dual-energy X-ray absorptiometry (DXA) bone density test.
Town Hall Provides Tools to Guide Patients Unsure About COVID-19 Vaccination
The ACR’s May 13 virtual town hall highlighted effective approaches rheumatology providers can take to convince patients to be vaccinated against COVID-19.
- « Previous Page
- 1
- …
- 141
- 142
- 143
- 144
- 145
- …
- 814
- Next Page »